IP Library Granted Patent US 8,158,596
Granted Patent B2
US 8,158,596 · App. 12/119,158 · Granted Apr 17, 2012

Materials and methods for FOXP3 tumor suppression

Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,158,596
App. No.
12/119,158
Granted
Apr 17, 2012
Kind
B2
Abstract

Provided herein are methods of treating a cancer in a subject comprising administering a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Methods of altering a phenotype of a cancer cell or tumor cell, methods of inhibiting growth of such cells, and methods of inducing apoptosis of these cells are also provided herein. These methods comprise contacting the cell with a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Further provided herein are diagnostic methods, comprising comparing the expression or structure of a FOXP3 protein or FOXP3 gene in a test sample to that of a normal or prior sample. A method of screening a test compound for anti-cancer activity comprising administering to cells the test compound and measuring FOXP3 protein or FOXP3 gene expression is moreover provided herein.

Claims (9)

1. A method of reducing tumor growth, said tumor comprising a breast cancer cell, a prostate cancer cell, or a thymic epithelial cancer cell, which cancer cell is sensitive to FOXP3 tumor suppressor activity in a subject, comprising administering directly to the cancer cell a recombinant expression vector comprising (i) a nucleic acid encoding a FOXP3 protein and (ii) a promoter sequence active in the cancer cell, wherein the promoter sequence is operably linked to said nucleic acid, wherein expression of said nucleic acid is in an amount effective to reduce tumor growth in the subject.

2. The method of claim 1 , wherein the nucleic acid encodes a FOXP3 protein comprising the amino acid sequence of any of SEQ ID NOs: 20 to 26 and 28 to 36.

3. The method of claim 1 , wherein the nucleic acid comprises the nucleotide sequence of any of SEQ ID NOs: 1 to 7 and 9 to 17.

4. The method of claim 1 , wherein the subject is a mammal.

5. The method of claim 4 , wherein the mammal is a human.

6. The method of claim 1 , wherein the method effectively reduces metastasis of the cancer cell.

7. The method of claim 1 , wherein the method further effectively increases survival of the subject.

8. The method of claim 1 , wherein the method effectively increases apoptosis of the cancer cell.

9. The method of claim 1 , wherein the method effectively increases killing of the cancer cell in said tumor.

Assignments (4)
CONFIRMATORY LICENSE Recorded Sep 30, 2010
From: UNIVERSITY OF MICHIGAN
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 025067/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2008
From: ZUO, TAO
To: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 021515/0518 →
CONFIRMATORY LICENSE Recorded Aug 18, 2008
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021401/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2008
From: LIU, YANG; ZHENG, PAN; CHANG, XING; WANG, LIZHONG; LIU, RUNHUA; WANG, YIN; LIU, YAN
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 021391/0033 →
Continuity (2)
Provisional Application 60917488 · May 11, 2007
Related Publication 20090325868A1 · Dec 31, 2009